BC
RVNC

Brookfield Corp’s Revance Therapeutics, Inc. RVNC Stock Holding History

Brookfield Corp’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58,727
Closed -$1.49M – 550
2023
Q2 		$1.49M Buy
+58,727
New +$1.83M 0.01% 435
2022
Q4 		– Sell
-124,347
Closed -$3.36M – 763
2022
Q3 		$3.36M Sell
124,347
-37,401
-23% -$759K 0.01% 348
2022
Q2 		$2.23M Sell
161,748
-35,375
-18% -$545K 0.01% 393
2022
Q1 		$3.84M Buy
+197,123
New +$2.99M 0.01% 296

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Brookfield Corp's RVNC Position: Q3 2023 in Review

Brookfield Corp sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 58,727 shares — an estimated $1.49M sold.

Brookfield Corp first reported a position in RVNC in Q1 2022 and held it in 4 quarters. The position peaked at $3.84M in Q1 2022. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Brookfield Corp reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 58,727 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $1.49M.
  • Brookfield Corp first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 4 quarters.
  • Brookfield Corp's Revance Therapeutics, Inc. position peaked at $3.84M in Q1 2022.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.